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DOI:10.1097/MOL.0b013e32835ec608Atherosclerosis is a chronic inflammatory reaction
of the arterial wall characterized by the infiltration
of inflammatory cells into the nascent athero-
sclerotic lesions leading to its growth and eventual
destabilization [1,2].
Transforming growth factor beta (TGFb), an
anti-inflammatory cytokine, is centrally involved
in balancing the immune response in atherosclero-
sis [3–5]. Recently, Lievens et al. [6
&&
] reported that
abrogation of TGFb signaling in dendritic cells leads
to a two-fold increase in lesion size and acceleration
of plaque inflammation. Furthermore, this over-
expression of dominant-inactive TGFb receptor
in CD11cþ cells increased cytokine production
and T-cell content in the plaque. In vitro, dendritic
cells deficient in TGFb signaling displayed a pro-
found inflammatory phenotype promoting T-cell
activation, proliferation, and differentiation into
effector cells, thus providing a mechanistic link to
the changes observed in the vasculature. Taken
together, this study suggests a potential therapeutic
approach in which dendritic cell-specific promotion
of TGF signaling may dampen atherosclerosis
without the detrimental profibrotic and neoplastic
complications caused by systemic TGFR activation.
Regulatory T cells (Tregs) are increasingly recog-
nized as potent atheroprotective players [7]. Inter-
estingly, TGFb plays a dual role in Tregs, as it
regulates their differentiation and function but also
is secreted as one of the most potent effector cyto-
kines. Treg numbers and function were modulated
in the atherosclerosis models either by direct
adoptive transfer or by indirect measures such as
vaccination [8]. Treg function is also mediated
by indoleamine 2,3-dioxygenase (IDO) and IDO-
catalyzed tryptophan metabolism [9]. The trypto-
phan metabolite 3-hydroxyanthranilic acid (3-HAA)
inhibits inflammation in different experimental
autoimmune disease models by repressing pro-
inflammatory T cells and increasing the percentage
of Tregs [10]. Zhang et al. [11
&&
] now show that
3-HAA reduced atherosclerotic lesion formation
in hyperlipidemic mice. Interestingly, 3-HAAilliams & Wilkins. Unaut
Health | Lippincott Williams & Wilktreatment also reduced plasma lipid levels, indicat-
ing beneficial action on both the inflammatory and
the lipid-metabolic component of atherosclerosis
[12].
Interleukin (IL)-13 is an anti-inflammatory
cytokine acting predominantly on monocytic cells.
Cardilo-Reis et al. [13
&
] reported that administration
of IL-13 increases collagen and reduces macrophage
content within murine atherosclerotic lesions
yielding a stable plaque phenotype. In addition,
IL-13 promoted an alternatively activated macro-
phage phenotype. In vitro, these macrophages show
enhanced oxLDL uptake but differentiate to a lesser
extent into foam cells compensated by enhanced
cholesterol efflux. Vice versa, atherosclerosis is
exacerbated in mice reconstituted with bone
marrow deficient in IL-13.
MicroRNAs (miRNAs) are small, noncoding,
regulatory, short RNA molecules that modify gene
expression by targeting messenger RNA (mRNA) for
degradation or repressing their translation [14
&
].
Circulating miRNAs correlate with cardiovascular
risk and clinical manifestations such as myocardial
infarction. Recently, Nazari-Jahantigh et al. [15
&&
]
discovered the involvement of miRNA-155 in the
progression of atherosclerosis by influencing macro-
phage subsets. Increased expression of miRNA-155
was observed following partial carotid ligation and
in bone marrow-derived and M1-polarized macro-
phages. Furthermore, miRNA-155 promoted BCL6-
mediated transcription of CCL2, a chemokinehorized reproduction of this article is prohibited.
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Co
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sclerotic plaque.
Taken together, these experimental studies
detailing the anti-inflammatory mechanisms may
lead to the development of targeted interventions
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